Efungumab ? Monoclonal antibody Type Single-chain variable fragment Source Human Target fungal Hsp90 Clinical data Pregnancy cat. ? Legal status ? Routes Intravenous Pharmacokinetic data Bioavailability Not applicable (IV only) Protein binding High Half-life 1–2 hours Identifiers ATC code None UNII Chemical data Formula ? Mol. mass Approximately 27.2 kDa (what is this?)
Efungumab (trade name Mycograb) is a drug developed by NeuTec Pharma (a subsidiary of Novartis), intended to treat invasive Candida infection in combination with amphotericin B. The European Medicines Agency has twice refused to grant marketing authorization for Mycograb, citing product safety and quality issues.
- ^ European Medicines Agency (2007). PDF (370 KiB). London: European Medicines Agency. Retrieved on 2007-11-20. Detailed assessment report with comprehensive overview of reasons for refusal of marketing authorization.
- ^ World Health Organization (2006). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 95" (PDF). WHO Drug Information 20 (2): 48. http://whqlibdoc.who.int/druginfo/20_2_2006_INN95.pdf.
Monoclonal antibodies for infectious disease and toxins Fungal ("-fung-")Human ("-fungu-")Efungumab Viral ("-vi(r)-")Human ("-viru-")Humanized ("-vizu-") Bacterial ("-ba(c)-")Human ("-bacu-")Mouse ("-baco-")Chimeric ("-baxi-")Humanized ("-bazu-") Toxin ("-tox(a)-")Humanized ("-toxazu-") This antiinfective drug article is a stub. You can help Wikipedia by expanding it. This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.